Combined Analysis of Phase III Trials Evaluating [99mTc]Tilmanocept and Vital Blue Dye for Identification of Sentinel Lymph Nodes in Clinically Node-Negative Cutaneous Melanoma

Combined Analysis of Phase III Trials Evaluating [99mTc]Tilmanocept and Vital Blue Dye for Identification of Sentinel Lymph Nodes in Clinically Node-Negative Cutaneous Melanoma

[(99m)Tc]Tilmanocept is a CD206 receptor-targeted radiopharmaceutical designed for sentinel lymph node (SLN) identification. Two nearly identical nonrandomized phase III trials compared [(99m)Tc]tilmanocept to vital blue dye.Patients received [(99m)Tc]tilmanocept and blue dye. SLNs identified intrao...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Główni autorzy: Vernon K. Sondak, Dennis W. King, Jonathan S. Zager, Schlomo Schneebaum, Julian Kim, Stanley P. L. Leong, Mark B. Faries, Bruce J. Averbook, Steve R. Martinez, Christopher A. Puleo, Jane L. Messina, Lori Christman, Anne M. Wallace
Format: Artigo
Język:angielski
Wydane: 2012
Dostęp online:https://doi.org/10.1245/s10434-012-2612-z
https://link.springer.com/content/pdf/10.1245/s10434-012-2612-z.pdf
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Internet

https://doi.org/10.1245/s10434-012-2612-z
https://link.springer.com/content/pdf/10.1245/s10434-012-2612-z.pdf

Podobne zapisy